Table 1.
Baseline patient characteristics (post-randomisation) and changes in TKV and eGFR, as observed in the placebo arm of TEMPO 3:4 study [12, 39]
| Placebo arm (N = 484) |
||
|---|---|---|
| Male gender (n, %) | 251 (51.9) | |
| TKV (mL) | ||
| Baseline (mean, SD) | 1667.5 (873.1) | |
| Annual change (mean, SD) | 114.4 (113.2) | |
| eGFRa | 1/SC ([mg/mL]−1) | CKD-Epi (mL/min/1.73 m2) |
| Baseline (mean, SD) | 104.30 (33.87) | 82.14 (22.73) |
| Annual change (mean, SD) | −3.682 (6.361) | −3.568 (4.495) |
1/SC reciprocal of serum creatinine, CKD-Epi Chronic Kidney Disease Epidemiology Collaboration, eGFR estimated glomerular filtration rate, SD standard deviation, TKV total kidney volume
aeGFR was measured using both the reciprocal of serum creatinine (1/SC) and Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation [12]